SOURCE: Electro-Optical Sciences, Inc.

June 10, 2009 07:30 ET

Electro-Optical Sciences Appoints Anne Egger to Board of Directors

IRVINGTON, NY--(Marketwire - June 10, 2009) - Electro-Optical Sciences, Inc. ("EOS") (NASDAQ: MELA) today announced that it has appointed Anne Egger to its Board of Directors. Ms. Egger brings more than 20 years of experience in dermatology sales and marketing to the EOS Board.

"Anne's acceptance of a position on our Board has energized us," said Joseph V. Gulfo, MD, President and CEO of Electro-Optical Sciences. "Having submitted the MelaFind® PMA last week, we are in the midst of a transformation from an R&D focused organization to a commercial business. I can think of no one more savvy and dynamic to help lead us in this new direction. Anne's 28 years of experience in pharmaceutical sales and marketing and two decades in dermatology will prove invaluable to EOS as we move forward with our plans for MelaFind, our breakthrough non-invasive, point of care, computerized system for early melanoma detection."

Since retiring in March of 2009, Ms. Egger has been working with EOS as a consultant. Prior to this, in her time at Galderma, Ms. Egger most recently served as head of the US Sales and Marketing division. She was also an Industry Adjunct member of the American Academy of Dermatology for the past 7 years, and a member of the American Society of Dermatologic Surgeons Industry Council for the last 5 years.

Ms. Egger's appointment is effective immediately. This additional appointment brings the total number of Directors of the company to eight. Ms. Egger will continue to consult for the company.

About Electro-Optical Sciences

Electro-Optical Sciences is a medical technology company focused on developing MelaFind®, a non-invasive and objective computer vision system intended to aid in the early detection of melanoma. EOS designed MelaFind® to assist in the evaluation of pigmented skin lesions, including atypical moles, which have one or more clinical or historical characteristics of melanoma, before a final decision to biopsy has been rendered. MelaFind® acquires and displays multi-spectral (from blue to near infrared) digital images of pigmented skin lesions and uses automatic image analysis and statistical pattern recognition to help identify lesions to be considered for biopsy to rule out melanoma.

On June 4, the company announced the submission of the Premarket Approval application for MelaFind to FDA. Although the application is subject to FDA's expedited review procedures, EOS cannot predict neither the timing of FDA's decision on the PMA application nor the outcome. FDA approval is required prior to marketing in the United States.

For more information on EOS, visit www.eosciences.com.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved. Actual results may differ materially from our beliefs or expectations due to economic, business, competitive, market and regulatory factors.

Contact Information

  • For further information contact:

    Investors
    David Carey
    Lazar Partners Ltd.
    212-867-1768

    Media
    Hollister Hovey
    Lazar Partners Ltd.
    646-871-8482